Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | PRKACA | P17612 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | PRKX | P51817 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6969527 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL226317 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30069136 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29378010 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL124161 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29677841 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2456059 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL507871 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2461354 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29781011 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| US-20240060050-A1 | CANINE HEPATIC ORGANOIDS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2024-02-22 | — | — | US | claimed |
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | claimed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | claimed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4079756-A1 | PROLIFERATIVE LIVER ORGANOID, METABOLICCALY ACTIVATED LIVER ORGANOID, AND USE THEREOF | JSR Corporation (JP) | 2022-10-26 | — | — | EP | claimed |
| WO-2022197935-A1 | CANINE HEPATIC ORGANOIDS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4045631-A1 | PRODUCTION OF SKELETAL MUSCLE CELLS AND SKELETAL MUSCLE TISSUE FROM PLURIPOTENT STEM CELLS | Georg-August-Universität Göttingen (DE) | 2022-08-24 | — | — | EP | claimed |
| CN-114929858-A | Production of skeletal muscle cells and tissues from pluripotent stem cells | 乔治-奥古斯特-哥廷根大学公法大学医学基金会 | 2022-08-19 | — | — | CN | claimed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736949-A2 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2022023451-A1 | MASS PRODUCTION OF HUMAN PLURIPOTENT STEM CELL DERIVED CARDIAC STROMAL CELL | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2022-02-03 | — | — | WO | disclosed |
| EP-3945133-A1 | MASS PRODUCTION OF HUMAN PLURIPOTENT STEM CELL DERIVED CARDIAC STROMAL CELL | Georg-August-Universität Göttingen (DE) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK2 5/4885ROCK1 4/4885PRKACA 2049/4885 |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | TRPM5, TRPM6, TRPM2 | ROCK2 3415/4885ROCK1 3559/4885PRKACA 650/4885 |
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | NTRK2, GRK6, GRK1 | ROCK2 7/4885ROCK1 18/4885PRKACA 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.